# Gleevec in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma

> **NCT00684411** · PHASE2 · COMPLETED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 12 (actual)

## Conditions studied

- T Cell Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** Imatinib mesylate

## Key facts

- **NCT ID:** NCT00684411
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2013-10
- **Final completion:** 2013-10
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2017-01-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00684411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00684411, "Gleevec in Relapsed/Refractory T Cell Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00684411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*